On the other hand, the data showed that failing to achieve early complete donor chimerism, using a very stringent threshold of <0.2% recipient DNA in CD33+ cells during the first 60 days after HSCT, was associated with increased risk of relapse and consequently has potential to be used for risk-stratification of AML patients post-HSCT. Here, CD33 is linked to acute myeloid leukemia.